Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
43 participants
OBSERVATIONAL
2023-06-30
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AD patients frequently present hyperhomocysteinemia, a consequence of a dysfunction of monocarbon metabolism. Homocysteine is an amino acid involved in the metabolism of methionine and cysteine. High concentrations of homocysteine can be deleterious to the central nervous system.
Most prospective studies have shown that elevated homocysteine is a predictor of undefined cognitive impairment or AD. Other studies have focused on clinical data and, in particular, on cognitive function. For example, a meta-analysis found an inverse correlation between MMSE score and homocysteine level.
Thus, our study seeks to evaluate the impact of hyperhomocysteinemia on the severity and early onset of AD, while knowing the presence or absence of genetic risk factors associated with AD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease (HO-MA)
NCT06168955
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
NCT02811653
Brain Imaging in Alzheimer's Disease
NCT00039702
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
NCT00381381
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with Alzheimer's Disease
Patients with Alzheimer's disease
Retrospective study of clinical features
Retrospective study of clinical features
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Retrospective study of clinical features
Retrospective study of clinical features
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive CSF biomarkers
* age of onset \< 75 years
* already benefited from a previous research of Alzheimer's disease genetic features (PSEN1, PSEN2, APP, APOE)
* already benefited from a previous research of homocysteine cycle (monocarbon metabolism) by complete exome/clinical exome or panel
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
RENAUD Mathilde
Principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023PI049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.